Higher Serum Glucose Levels Are Associated with Cerebral Hypometabolism in Alzheimer Regions

Overview

Journal Neurology

Specialty Neurology

Date 2013 Mar 29

PMID 23535495

Citations 47

Authors

Christine M Burns

Kewei Chen

Alfred W Kaszniak

Wendy Lee

Gene E Alexander

Daniel Bandy

Adam S Fleisher

Richard J Caselli

Eric M Reiman

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate whether higher fasting serum glucose levels in cognitively normal, nondiabetic adults were associated with lower regional cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer disease (AD).

Methods: This is a cross-sectional study of 124 cognitively normal persons aged 64 ± 6 years with a first-degree family history of AD, including 61 APOEε4 noncarriers and 63 carriers. An automated brain mapping algorithm characterized and compared correlations between higher fasting serum glucose levels and lower [(18)F]-fluorodeoxyglucose-PET rCMRgl measurements.

Results: As predicted, higher fasting serum glucose levels were significantly correlated with lower rCMRgl and were confined to the vicinity of brain regions preferentially affected by AD. A similar pattern of regional correlations occurred in the APOEε4 noncarriers and carriers.

Conclusions: Higher fasting serum glucose levels in cognitively normal, nondiabetic adults may be associated with AD pathophysiology. Findings suggest that the risk imparted by higher serum glucose levels may be independent of APOEε4 status. This study raises additional questions about the role of the metabolic process in the predisposition to AD and supports the possibility of targeting these processes in presymptomatic AD trials.

Citing Articles

Relationships Between Brain Glucose Metabolism Patterns and Impaired Glycemic Status: A Systematic Review of FDG-PET Studies With a Focus on Alzheimer's Disease.

Soltani S, Dolatshahi M, Soltani S, Khazaei K, Rahmani M, Raji C Hum Brain Mapp. 2025; 46(4):e70180.

PMID: 40033766 PMC: 11876560. DOI: 10.1002/hbm.70180.

Trends in Global Burden of Alzheimer's Disease and Other Dementias Attributable to High Fasting Plasma Glucose, 1990-2021.

Ilic I, Jakovljevic V, Zivanovic Macuzic I, Ravic-Nikolic A, Ilic M, Sorak M Medicina (Kaunas). 2024; 60(11).

PMID: 39596969 PMC: 11596767. DOI: 10.3390/medicina60111783.

Hyperglycemia selectively increases cerebral non-oxidative glucose consumption without affecting blood flow.

Blazey T, Lee J, Snyder A, Goyal M, Hershey T, Arbelaez A bioRxiv. 2024; .

PMID: 39314314 PMC: 11418958. DOI: 10.1101/2024.09.05.611035.

Process validation and preclinical development of a new PET cerebral blood flow tracer [C]MMP for initial clinical trials.

Toyohara J, Tago T, Sakata M EJNMMI Radiopharm Chem. 2024; 9(1):53.

PMID: 39042331 PMC: 11266321. DOI: 10.1186/s41181-024-00285-9.

Fasting Plasma Glucose Levels and Longitudinal Motor and Cognitive Outcomes in Parkinson's Disease Patients.

Choi K, Ryu D, Oh Y, Kim J J Mov Disord. 2024; 17(2):198-207.

PMID: 38444294 PMC: 11082616. DOI: 10.14802/jmd.23264.

References

Craft S, Baker L, Montine T, Minoshima S, Watson G, Claxton A . Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2011; 69(1):29-38. PMC: 3260944. DOI: 10.1001/archneurol.2011.233. View

Yaffe K . Metabolic syndrome and cognitive disorders: is the sum greater than its parts?. Alzheimer Dis Assoc Disord. 2007; 21(2):167-71. DOI: 10.1097/WAD.0b013e318065bfd6. View

Kawasaki K, Ishii K, Saito Y, Oda K, Kimura Y, Ishiwata K . Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping. Ann Nucl Med. 2008; 22(3):191-200. DOI: 10.1007/s12149-007-0099-7. View

Reiman E, Caselli R, Yun L, Chen K, Bandy D, Minoshima S . Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996; 334(12):752-8. DOI: 10.1056/NEJM199603213341202. View

Langbaum J, Chen K, Launer L, Fleisher A, Lee W, Liu X . Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2011; 33(4):827.e11-9. PMC: 3236809. DOI: 10.1016/j.neurobiolaging.2011.06.020. View

Rasgon N, Kenna H, Wroolie T, Kelley R, Silverman D, Brooks J . Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging. 2009; 32(11):1942-8. PMC: 2891925. DOI: 10.1016/j.neurobiolaging.2009.12.005. View

Reiman E, Chen K, Alexander G, Caselli R, Bandy D, Osborne D . Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005; 102(23):8299-302. PMC: 1149416. DOI: 10.1073/pnas.0500579102. View

Xu W, Qiu C, Winblad B, Fratiglioni L . The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes. 2006; 56(1):211-6. DOI: 10.2337/db06-0879. View

Cherbuin N, Sachdev P, Anstey K . Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. Neurology. 2012; 79(10):1019-26. DOI: 10.1212/WNL.0b013e31826846de. View

10.

Gottesman I, Gould T . The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003; 160(4):636-45. DOI: 10.1176/appi.ajp.160.4.636. View

11.

Baker L, Cross D, Minoshima S, Belongia D, Watson G, Craft S . Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2010; 68(1):51-7. PMC: 3023149. DOI: 10.1001/archneurol.2010.225. View

12.

Reiman E, Chen K, Langbaum J, Lee W, Reschke C, Bandy D . Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage. 2009; 49(1):169-76. PMC: 2888804. DOI: 10.1016/j.neuroimage.2009.07.025. View

13.

Caselli R . Age-related memory decline and apolipoprotein E e4. Discov Med. 2009; 8(41):47-50. View

14.

Craft S . The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009; 66(3):300-5. PMC: 2717716. DOI: 10.1001/archneurol.2009.27. View

15.

Panza F, Frisardi V, Capurso C, Imbimbo B, Vendemiale G, Santamato A . Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis. 2010; 21(3):691-724. DOI: 10.3233/JAD-2010-091669. View

16.

Loessner A, Alavi A, Lewandrowski K, Mozley D, Souder E, Gur R . Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med. 1995; 36(7):1141-9. View

17.

de la Monte S . Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs. 2011; 72(1):49-66. PMC: 4550303. DOI: 10.2165/11597760-000000000-00000. View

18.

Silverman D, Small G, Chang C, Lu C, Kung De Aburto M, Chen W . Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001; 286(17):2120-7. DOI: 10.1001/jama.286.17.2120. View

19.

Luchsinger J . Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis. 2012; 30 Suppl 2:S185-98. PMC: 3372666. DOI: 10.3233/JAD-2012-111433. View

20.

Reiman E, Langbaum J, Fleisher A, Caselli R, Chen K, Ayutyanont N . Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011; 26 Suppl 3:321-9. PMC: 3343739. DOI: 10.3233/JAD-2011-0059. View